"Comprehensive Diabetes Control: VOGLIGOLD G3 M0.3"

VOGLIGOLD G3 M0.3

Voglibose 0.3 mg, Glimepiride 3 mg & Metformin Hydrochloride 500 mg

Introduction to VOGLIGOLD G3 M0.3

VOGLIGOLD G3 M0.3 is a combination medication containing Voglibose 0.3 mg, Glimepiride 3 mg, and Metformin Hydrochloride 500 mg. This article delves into the therapeutic benefits, dosage regimen, mechanism of action, potential side effects, and precautions associated with this comprehensive approach to diabetes management.

Components and Mechanisms

• Voglibose (0.3 mg): Inhibits alpha-glucosidase enzymes, reducing carbohydrate absorption and postprandial glucose levels.
• Glimepiride (3 mg): Stimulates insulin release from pancreatic beta cells, aiding in glucose utilization and lowering blood sugar levels.
• Metformin Hydrochloride (500 mg): Improves insulin sensitivity, decreases hepatic glucose production, and enhances peripheral glucose uptake.

Benefits of VOGLIGOLD G3 M0.3

• Multifaceted Glucose Control: Addresses various aspects of diabetes pathophysiology, including postprandial hyperglycemia and insulin resistance.
• HbA1c Reduction: Long-term use can lead to significant reductions in HbA1c levels, reflecting improved overall diabetes management.
• Cardiovascular Protection: Metformin's cardioprotective properties complement Glimepiride's glucose-lowering effects, reducing cardiovascular risk.

Dosage and Administration

• Optimal Dosage: The standard dosage is one tablet taken orally with meals, typically once daily or as directed by a healthcare professional.
• Patient Education: Importance of adherence, meal planning, regular exercise, and monitoring blood glucose levels should be emphasized.
• Individualized Approach: Dosage adjustments may be necessary based on individual response and glycemic control goals.

Side Effects and Precautions

• Hypoglycemia: Glimepiride carries a risk of hypoglycemia, especially in elderly patients or those with compromised kidney function.
• GI Tolerability: Voglibose may cause mild gastrointestinal symptoms like bloating or diarrhea, which usually resolve with continued use.
• Monitoring Parameters: Regular monitoring of blood glucose, renal function, and potential vitamin B12 deficiency is recommended during therapy.

Conclusion

VOGLIGOLD G3 M0.3, combining Voglibose, Glimepiride, and Metformin, offers a comprehensive approach to diabetes management. This combination therapy provides multifaceted benefits in glucose control, HbA1c reduction, and cardiovascular risk mitigation. Consult your healthcare provider for personalized guidance on using VOGLIGOLD G3 M0.3 for diabetes management.

Steris Healthcare Pvt Ltd, founded by a group of expert professionals in the pharmaceutical industry in February 2018, operates as Sterispharma. This company, which is based in Navi Mumbai, holds certifications from WHO, GMP, and ISO. Its commitment is to provide high-quality drugs at affordable prices to its customers throughout India, following the rigorous guidelines set by the WHO. Steris offers the convenience of an online pharmacy where customers can easily buy medicines and enjoy the benefit of home delivery. At Steris, the mission is to supply a wide array of healthcare products designed to meet the varied needs of the medical community. Whether it is advanced treatments, medications for rare conditions, or basic health necessities, Sterispharma strives to serve the healthcare industry’s broad demands. The extensive product lineup from Steris includes treatments for various health areas such as Cardiology, Asthma, Respiratory issues, Nasal conditions, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infectives/antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental care, and Dermatology.

  For further information: 

 EMAIL:  info@sterispharma.com  / contact@sterispharma.com   

 CALL/WHATSAPP: 7877551268, 7849827488

   BUY NOW